Liling Huang

Liling Huang

Auto-generated profile, based on publicly available information

Liling Huang

Department of Hematology, China-Japan Friendship Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2010 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
WSWeiguo Sui
Weiguo Sui
LHLiling Huang
Liling Huang
YDYong Dai
Yong Dai
JCJiejing Chen
Jiejing Chen
QYQiang Yan
Qiang Yan
HHHuang Huang
Huang Huang

21 October 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
LHLiling Huang
Liling Huang
TXTongji Xie
Tongji Xie
FZFuqiang Zhao
Fuqiang Zhao
YFYu Feng
Yu Feng
HZHaohua Zhu
Haohua Zhu
YSYuan-kai Shi
Yuan-kai Shi
Background. It is still an unmet clinical need to identify potent biomarkers for immunotherapy on patients with lung squamous cell carcinoma (LUSC). Methods. In this study, we explored the differentially expressed genes (DEGs) that were simultaneously correlated with four pathways (i.e. CD8+αβT cell proliferation/differentiation/activation pathways and ferroptosis pathway) and possibly related to the remodeling of tumor microenvironment via the TCGA-LUSC dataset. Besides, four GEO datasets (GSE157009, GSE157010, GSE19188, and GSE126045) and IMvigor210 dataset were utilized for confirmation and validation. Results. The co-downregulated DEG DLX2 was selected for further analysis. Function enrichment analysis revealed that low-expression of DLX2 was closely related to various immune-related pathways like T/B/NK cell mediated immunity, interferon gamma/alpha response, and various autoimmune disease. DLX2-downregulated group was enriched in more immune-activating cells and lower tumor immune dysfunction and exclusion (TIDE) score. Via the Cancer Immunome Atlas (TCIA) database, lower expression of DLX2 was also found to be associated with better IPS score of PD-1/PD-L1 blockade ( ) as well as CTLA-4 combined with PD-1/PD-L1 blockade ( ). Furthermore, patients in DLX2-low group were found to have significant longer median OS than those in DLX2-high group in IMvigor210 dataset (10.8 vs 7.4 months; hazard ratio [HR]=0.74, 95% confidence interval [95%CI] 0.57-0.96; ). Conclusions. Our study on an integrated bioinformatical analysis implied that DLX2 could be served as a promising indicator for remodeling tumor microenvironment status and predicting ICI response of patients with LUSC.

25 August 2017 in BMC Neurology
Verified
Journal Article
Open access
PDF file
JLJian-Ming Li
Jian-Ming Li
LHLi-Ling Huang
Li-Ling Huang
FLFei Liu
Fei Liu
BTBeisha Tang
Beisha Tang
XYXiao-Xin Yan
Xiao-Xin Yan
Cerebral amyloid angiopathy (CAA) is characterized by the deposition of ß-amyloid peptides (Aß) in and surrounding the wall of microvasculature in the central nervous system, together with parenchymal amyloid plaques collectively referred to as cerebral amyloidosis, which occurs in the brain commonly among the elderly and more frequently in patients with Alzheimer’s disease (AD). CAA is associated with vascular injury and may cause devastating neurological outcomes. No therapeutic approach is available for this lesion to date. ß-Secretase 1 (BACE1) is the enzyme initiating Aß production. Brain permeable BACE1 inhibitors targeting primarily at the parenchymal plaque pathology are currently evaluated in clinical trials. This article presents findings in support of a role of BACE1 elevation in the development of CAA, in addition to plaque pathogenesis. The rationale, feasibility, benefit and strategic issues for developing BACE1 inhibitors against CAA are discussed. Brain impermeable compounds are considered preferable as they might exhibit sufficient anti-CAA efficacy without causing significant neuronal/synaptic side effects. Early pharmacological intervention to the pathogenesis of CAA is expected to provide significant protection for cerebral vascular health and hence brain health. Brain impermeable BACE1 inhibitors should be optimized and tested as potential anti-CAA therapeutics.

1 November 2022 in Epigenomics
Verified
Journal Article
Closed access
TXTongji Xie
Tongji Xie
GFGuangyu Fan
Guangyu Fan
LHLiling Huang
Liling Huang
NLNing Lou
Ning Lou
XHXiaohong Han
Xiaohong Han
YSYuan-kai Shi
Yuan-kai Shi
Aim: To find biomarkers for immunity and immunotherapy in lung adenocarcinoma (LUAD) through multiomics analysis. Materials & methods: The multiomics data of patients with LUAD were downloaded from... Plain language summary Our research provides a new and robust method to select biomarkers based on the tumor immune microenvironment. Our research finds that a new epigenomic and transcriptomic bio...

1 May 2026 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
LHLiling Huang
Liling Huang
KCKai Chen
Kai Chen
MWMin Wang
Min Wang
CGChao Guo
Chao Guo
YLYang Li
Yang Li
ZLZhenling Li
Zhenling Li
Background: The advent of novel therapies including chimeric antigen receptor (CAR) T cells, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs), has markedly improved clinical outcomes for relapsed or refractory large B-cell lymphoma (R/R LBCL). However, direct comparisons of efficacy and safety among systemic treatments for R/R LBCL are lacking, complicating clinical decision-making. Methods: A systematic literature search was conducted across PubMed, Embase, and the Cochrane Library to identify eligible randomized controlled trials (RCTs). A Bayesian network meta-analysis (NMA) was performed to evaluate the systemic therapies across transplant-eligible and transplant-ineligible patients with R/R LBCL. The primary endpoint was progression-free survival (PFS), secondary endpoints included event-free survival (EFS), overall survival (OS), objective response rate (ORR) and grade ≥3 treatment-emergent adverse events (TEAEs). Results: The analysis included 14 RCTs comprising a total of 3,329 patients. Among the transplant-eligible cohort (7 evaluated regimens), CAR-T therapies maximized disease control; lisocabtagene maraleucel (liso-cel) ranked highest for PFS [hazard ratio (HR) =0.42; 95% credible intervals (CrI): 0.28–0.64] and EFS (HR =0.37, 95% CrI: 0.26–0.54), whereas axicabtagene ciloleucel (axi-cel) was associated with the highest incidence of grade ≥3 TEAEs [risk ratio (RR) =2.09; 95% CrI: 1.08–4.19]. In the transplant-ineligible cohort (9 evaluated regimens), glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) ranked highest for PFS (HR =0.32; 95% CrI: 0.23–0.45), while polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) yielded the maximum benefit for OS (HR =0.42; 95% CrI: 0.24–0.73) and ORR [odds ratio (OR) =5.21; 95% CrI: 2.01–14.3]. Both regimens were associated with higher toxicities, but remained overall manageable. Conclusions: This NMA provides a comprehensive comparison of systemic treatment strategies for R/R LBCL regarding efficacy and safety profiles.